keyword
MENU ▼
Read by QxMD icon Read
search

Augmentation depression

keyword
https://www.readbyqxmd.com/read/28338544/associations-between-medication-class-and-subsequent-augmentation-of-depression-treatment-in-privately-insured-us-adults
#1
Omid Ameli, Rene Soria-Saucedo, Eric G Smith, Howard J Cabral, Marina Soley-Bori, Lewis E Kazis
IMPORTANCE: Treatment augmentation is an important clinical decision in the pharmacotherapy for depression, yet few studies have examined the rates of treatment augmentation by medication class. OBJECTIVE: The aim of this study was to examine which initial pharmacotherapies for depression are more likely than others to result in subsequent treatment augmentation. METHODS: This study is a retrospective cohort analysis of administrative data of 214,705 privately insured US adults between the age of 18 and 64 years who were diagnosed with a new episode of depression in 2009...
March 23, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/28334441/flexible-parasympathetic-responses-to-sadness-facilitate-spontaneous-affect-regulation
#2
Jonathan P Stange, Jessica L Hamilton, David M Fresco, Lauren B Alloy
The ability of the parasympathetic nervous system to flexibly adapt to changes in environmental context is thought to serve as a physiological indicator of self-regulatory capacity, and deficits in parasympathetic flexibility appear to characterize affective disorders such as depression. However, whether parasympathetic flexibility (vagal withdrawal to emotional or environmental challenges such as sadness, and vagal augmentation during recovery from sadness) could facilitate the effectiveness of adaptive affect regulation strategies is not known...
March 23, 2017: Psychophysiology
https://www.readbyqxmd.com/read/28331332/clinical-role-of-brexpiprazole-in-depression-and-schizophrenia
#3
REVIEW
Nishant B Parikh, Diana M Robinson, Anita H Clayton
Brexpiprazole, a serotonin-dopamine activity modulator, is the second D2 partial agonist to come to market and has been approved for the treatment of schizophrenia and as an adjunctive treatment in major depressive disorder. With less intrinsic activity than aripiprazole at the D2 receptor and higher potency at 5-HT2A, 5-HT1A, and α1B receptors, the pharmacological properties of brexpiprazole suggest a more tolerable side effect profile with regard to akathisia, extrapyramidal dysfunction, and sedation. While no head-to-head data are currently available, double-blind placebo-controlled studies show favorable results, with the number needed to treat (NNT) vs placebo of 6-15 for response in acute schizophrenia treatment and 4 for maintenance...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28319691/trajectories-of-maternal-depressive-symptoms-in-the-early-childhood-period-and-family-wide-clustering-of-risk
#4
Sheri Madigan, Mark Wade, André Plamondon, Jennifer M Jenkins
BACKGROUND: Previous research on individual differences in the course of maternal depressive symptoms has yielded inconsistent findings, with significant variation in the number and pattern of trajectories identified. In addition, missing from the literature is a comprehensive examination of predictors and longitudinal consequences of particular depression trajectories. METHOD: Participants in this study included a community cohort of 501 women assessed for depression using the Center for Epidemiologic Depression Scale at infant age 2, 18, 36, and 54 months...
March 7, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28318897/efficacy-of-off-label-augmentation-in-unipolar-depression-a-systematic-review-of-the-evidence
#5
REVIEW
Julia Kleeblatt, Felix Betzler, Laura L Kilarski, Tom Bschor, Stephan Köhler
Treatment of unipolar depression with currently available antidepressants is still unsatisfactory. Augmentation with lithium or second generation antipsychotics is an established practice in non-responders to antidepressant monotherapy, but is also associated with a substantial non-response rate and with non-tolerance. Based on a systematic review of the literature, including meta-analyses, randomized controlled trials (RCTs), non-randomized comparative studies and case studies, off-label augmentation agents (administered in addition to an antidepressant, without FDA approval for treatment of MDD) were identified and evaluated regarding their efficacy using levels of evidence...
March 16, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28317392/pharmacotherapy-of-major-depression-in-late-life-what-is-the-role-of-new-agents
#6
Kinjal Patel, Petal S Abdool, Tarek K Rajji, Benoit H Mulsant
Evidence on the pharmacotherapy of late-life major depressive disorder (LLD) is scant. Most of the recommendations in existing clinical guidelines are based on expert opinions, extrapolations from data obtained in younger patients, or theoretical considerations. AREAS COVERED This article summarizes the recommendations from existing clinical guidelines and recent reviews on the treatment of LLD. Next, it discusses the potential role of newer antidepressants -vilazodone, levomilnacipran, and vortioxetine- based on a systematic search of the literature published during the past five years...
March 20, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/28300618/the-novel-and-potent-anti-depressive-action-of-triptolide-and-its-influences-on-hippocampal-neuroinflammation-in-a-rat-model-of-depression-comorbidity-of-chronic-pain
#7
Xiaofan Hu, Yulin Dong, Xiaohang Jin, Chunkui Zhang, Ting Zhang, Jie Zhao, Juan Shi, Jinlian Li
Chronic pain and depression frequently coexist in clinical setting, and current clinical treatments for this comorbidity have shown limited efficacy. Triptolide (T10), an active component of Tripterygium wilfordii Hook F., has been demonstrated to exert strong analgesic activities in experimental pain models, but whether it possesses anti-depressive actions remains unknown. Using a depression comorbidity of chronic pain rat model induced by spinal nerve ligation (SNL), we investigated the potency of T10 for the treatment of comorbid depression in comparison with a widely used antidepressant, fluoxetine (FLX)...
March 11, 2017: Brain, Behavior, and Immunity
https://www.readbyqxmd.com/read/28299207/zinc-in-the-monoaminergic-theory-of-depression-its-relationship-to-neural-plasticity
#8
REVIEW
Urszula Doboszewska, Piotr Wlaź, Gabriel Nowak, Maria Radziwoń-Zaleska, Ranji Cui, Katarzyna Młyniec
Preclinical and clinical studies have demonstrated that zinc possesses antidepressant properties and that it may augment the therapy with conventional, that is, monoamine-based, antidepressants. In this review we aim to discuss the role of zinc in the pathophysiology and treatment of depression with regard to the monoamine hypothesis of the disease. Particular attention will be paid to the recently described zinc-sensing GPR39 receptor as well as aspects of zinc deficiency. Furthermore, an attempt will be made to give a possible explanation of the mechanisms by which zinc interacts with the monoamine system in the context of depression and neural plasticity...
2017: Neural Plasticity
https://www.readbyqxmd.com/read/28294084/continuous-circular-cycling-as-a-predictor-of-treatment-response-in-bipolar-disorders-a-comprehensive-review-of-the-current-literature
#9
Antonio Tundo, Paola Cavalieri
Evidence from the literature suggests that, on average, 27% of patients with a bipolar disorder (BD) experience a continuous cycling course (CCC) and that this subgroup differs significantly from patients with a noncontinuous cycling course (N-CCC) with respect to sociodemographic characteristics and clinical presentation. The aim of the present paper is to review the studies that evaluated short- and long-term treatment responses in BD patients with CCC. The retrieved studies indicate that CCC is a significant predictor of poor response to long-term treatment with lithium (the odds of a response in the CCC group were 57% less than in the N-CCC group; p<0...
March 15, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28294051/further-evaluation-of-mechanisms-associated-with-the-antidepressant-like-signature-of-scopolamine-in-mice
#10
Anna E Martin, Douglas A Schober, Alexander Nikolayev, Vladimir V Tolstikov, Wesley H Anderson, Richard E Higgs, Ming-Shang Kuo, Anastasia Laksmanan, John T Catlow, Xia Li, Christian C Felder, Jeffrey M Witkin
Conventional antidepressants lack efficacy for many patients (treatment-resistant depression or TRD) and generally take weeks to produce full therapeutic response in others. Emerging data has identified certain drugs such as ketamine as rapidly-acting antidepressants for major depressive disorder and TRD. Scopolamine, a drug used to treat motion sickness and nausea, has also been demonstrated to function as a rapidly-acting antidepressant. The mechanisms associated with efficacy in TRD patients and rapid onset of action have been suggested to involve a-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor and mammalian target of rapamycin (mTOR) signaling...
March 9, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28293444/association-of-gait-characteristics-and-depression-in-patients-with-parkinson-s-disease-assessed-in-goal-directed-locomotion-task
#11
Péter Kincses, Norbert Kovács, Kázmér Karádi, Ádám Feldmann, Krisztina Dorn, Zsuzsanna Aschermann, Sámuel Komoly, Tibor Szolcsányi, Árpád Csathó, János Kállai
Introduction. In the genesis of Parkinson's disease (PD) clinical phenomenology the exact nature of the association between bradykinesia and affective variables is unclear. In the present study, we analyzed the gait characteristics and level of depression in PD and healthy volunteers. Methods. Patients with PD (n = 48) and healthy controls (n = 52) were recruited for the present study. Walking speed, stride length, and cadence were compared between groups while participants completed a goal-directed locomotion task under visually controlled (VC) and visually noncontrolled conditions (VnC)...
2017: Parkinson's Disease
https://www.readbyqxmd.com/read/28293046/efficacy-of-risperidone-augmentation-with-ondansetron-in-the-treatment-of-negative-and-depressive-symptoms-in-schizophrenia-a-randomized-clinical-trial
#12
Roya Samadi, Susan Soluti, Reza Daneshmand, Shervin Assari, Ali Akhoundpour Manteghi
BACKGROUND: Given the potential role of the 5-hydroxytryptamine-3 receptor in the pathogenesis of schizophrenia, this study was performed to determine whether ondansetron plus risperidone could reduce the negative and depressive symptoms in patients with treatment-resistant schizophrenia. METHODS: In a double-blinded, placebo-controlled, randomized trial (IRCT registration # 201112125280N7), in 2012-2013 in Mashhad, Iran, 38 patients with treatment-resistant schizophrenia received risperidone either combined with a fixed dose (4-8 mg/d) of ondansetron (n=18) or with a placebo (n=20) for 12 weeks...
January 2017: Iranian Journal of Medical Sciences
https://www.readbyqxmd.com/read/28291972/efficacy-safety-and-tolerability-of-augmentative-rtms-in-treatment-of-major-depressive-disorder-mdd-a-prospective-cohort-study-in-croatia
#13
Igor Filipcic, Zeljko Milovac, Strahimir Sucic, Tomislav Gajsak, Ivona Simunovic Filipcic, Ena Ivezic, Vjekoslav Aljinovic, Ivana Orgulan, Sandra Zecevic Penic, Zarko Bajic
BACKGROUND: An increasing body of research suggest that repetitive Transcranial Magnetic Stimulation (rTMS) is effective and safe treatment option for patients with major depressive disorder (MDD). The Psychiatric Hospital "Sveti Ivan" has the first TMS laboratory with rTMS and deep TMS (dTMS) in Croatia. The objective of this study was to assess the efficacy, safety and tolerability of augmentative rTMS treatment vs standard treatment in Croatian patients with major depressive disorder (MDD)...
March 2017: Psychiatria Danubina
https://www.readbyqxmd.com/read/28288438/epidemiology-of-pharmaceutically-treated-depression-and-treatment-resistant-depression-in-taiwan
#14
Daniel Fife, Yu Feng, Michael Yao-Hsien Wang, Chee-Jen Chang, Chia-Yih Liu, Hsiao-Ting Juang, Wesley Furnback, Jaskaran Singh, Bruce Wang
Epidemiologic data on treatment resistant depression (TRD) in Asia-Pacific countries are limited. We estimated the incidence of TRD in Taiwan using a cohort of 704,265 adults randomly sampled from Taiwan's National Health Insurance Research database for 2005. TRD was defined as a patient having pharmaceutically treated depression (PTD) not adequately responding to 2 antidepressant (AD) regimens, i.e., AD regimens that were followed by other AD regimens. Among 2751 PTD subjects, 576 (20.94%, 95% CI: 19.46, 22...
March 6, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/28284350/ketamine-upregulates-enos-expression-in-human-astroglial-a172-cells-possible-role-in-its-antidepressive-properties
#15
Yael Yuhas, Shai Ashkenazi, Eva Berent, Abraham Weizman
Ketamine is a potent anti-depressive agent. Nitric oxide plays an essential role in neuronal transmission and cerebral blood flow and has been implicated in the pathophysiology of major depressive disorder as well as cardiovascular functioning. We investigated the effect of ketamine on eNOS expression in human A172 astroglial cells. Ketamine (50-500μM) increased eNOS expression at 4-24h in a concentration-dependent manner. This effect was mediated by NMDA receptor, Akt inhibition and ERK1/2 activation and was synergistically augmented by rapamycin...
April 15, 2017: Journal of Neuroimmunology
https://www.readbyqxmd.com/read/28284107/clinical-characteristics-and-treatment-outcomes-of-patients-with-major-depressive-disorder-and-comorbid-anxiety-disorders-results-from-a-european-multicenter-study
#16
Markus Dold, Lucie Bartova, Daniel Souery, Julien Mendlewicz, Alessandro Serretti, Stefano Porcelli, Joseph Zohar, Stuart Montgomery, Siegfried Kasper
This naturalistic European multicenter study aimed to elucidate the association between major depressive disorder (MDD) and comorbid anxiety disorders. Demographic and clinical information of 1346 MDD patients were compared between those with and without concurrent anxiety disorders. The association between explanatory variables and the presence of comorbid anxiety disorders was examined using binary logistic regression analyses. 286 (21.2%) of the participants exhibited comorbid anxiety disorders, 10.8% generalized anxiety disorder (GAD), 8...
February 27, 2017: Journal of Psychiatric Research
https://www.readbyqxmd.com/read/28283422/importance-of-compensatory-heart-rate-increase-during-myocardial-ischemia-to-preserve-appropriate-oxygen-kinetics
#17
Sadamitsu Yoshida, Hitoshi Adachi, Makoto Murata, Junichi Tomono, Shigeru Oshima, Masahiko Kurabayashi
BACKGROUND: Myocardial ischemia induces cardiac dysfunction, resulting in insufficient oxygen supply to peripheral tissues and mismatched energy production during exercise. To relieve the insufficient oxygen supply, heart rate (HR) response is augmented; however, beta-adrenergic receptor blockers (BB) restrict HR response. Although BB are essential drugs for angina pectoris, the effect of BB on exercise tolerance in patients with angina has not been studied. The aim of this study was to clarify the importance of HR augmentation to preserve exercise tolerance in patients with angina pectoris...
March 7, 2017: Journal of Cardiology
https://www.readbyqxmd.com/read/28280892/antidepressant-pharmacotherapy-in-old-age-depression-a-review-and-clinical-approach
#18
REVIEW
Nathalie Pruckner, Vjera Holthoff-Detto
PURPOSE: Depression in old age is a disabling disease associated with functional and cognitive decline severely affecting quality of life. Studies specifically investigating antidepressant treatment for this special cohort of patients remain scarce and results are often conflicting. A narrative literature review was undertaken, synthesizing findings from published studies, systematic reviews, and treatment guidelines specifically conducted in elderly depressed patients to summarize implications and current recommendations as well as gaps in evidence for old-age pharmacologic treatment...
March 10, 2017: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28274920/h2o2-augments-cytosolic-calcium-in-nucleus-tractus-solitarii-neurons-via-multiple-voltage-gated-calcium-channels
#19
Tim D Ostrowski, Heather A Dantzler, Luis Polo-Parada, David D Kline
Reactive oxygen species (ROS) play a profound role in cardiorespiratory function under normal physiological conditions and disease states. ROS can influence neuronal activity by altering various ion channels and transporters. Within the nucleus tractus solitarii (nTS), a vital brainstem area for cardiorespiratory control, hydrogen peroxide (H2O2) induces sustained hyperexcitability following an initial depression of neuronal activity. The mechanism(s) associated with the delayed hyperexcitability are unknown...
March 8, 2017: American Journal of Physiology. Cell Physiology
https://www.readbyqxmd.com/read/28272863/serotonin-transporter-independent-actions-of-the-antidepressant-vortioxetine-as-revealed-using-the-sert-met172-mouse
#20
Alex G Nackenoff, Linda D Simmler, Nicole L Baganz, Alan L Pehrson, Connie Sánchez, Randy D Blakely
Selective serotonin (5-HT, SERT) reuptake inhibitors (SSRIs) are the most commonly prescribed treatments for depression. However, they have delayed efficacy and can induce side-effects that can encourage discontinuation. Recently, agents have been developed, including vortioxetine (Trintellix), that augment SERT blockade with interactions at other targets. At therapeutic doses, vortioxetine interacts with SERT as well as 5-HT1A, 5-HT1B, 5-HT3, and 5-HT7 receptors. We assessed the SERT-dependency of vortioxetine action using the SERT Met172 mouse model, which disrupts high-affinity interactions of many antidepressants with the transporter...
March 20, 2017: ACS Chemical Neuroscience
keyword
keyword
120069
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"